| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(5 months ago) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
Xeljanz Xr is owned by Pfizer.
Xeljanz Xr contains Tofacitinib Citrate.
Xeljanz Xr has a total of 5 drug patents out of which 1 drug patent has expired.
Expired drug patents of Xeljanz Xr are:
- US6965027
Xeljanz Xr was authorised for market use on 23 February, 2016.
Xeljanz Xr is available in tablet, extended release;oral dosage forms.
Xeljanz Xr can be used as a method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; a method of treating psoriatic arthritis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, and 87-98; a method of treating rheumatoid arthritis by administering the formulation of tofacitinib of claims 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 and 87-98; a method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98.
The generics of Xeljanz Xr are possible to be released after 14 March, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 23 February, 2016
Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method o...
Dosage: TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic